Remedy Robotics raises US$62 million to advance remote neurointerventional procedures

N1 system

Remedy Robotics has announced it has raised US$62 million in Series B funding to accelerate its mission of “delivering flawless, immediate robotic care to all patients, regardless of location”.

According to the company, this funding will support several major milestones, including a planned pivotal clinical trial in partnership with the University of California (UC; Oakland, USA) and advancement toward US Food and Drug Administration (FDA) approval of its N1 system for neurovascular interventions. Remedy also plans to deploy prototype N1 systems across its network of clinical partners, including through its strategic partnerships with the Society of Vascular and Interventional Neurology’s (SVIN) Mission Thrombectomy and the Australian Stroke Alliance, while continuing to advance the system’s “industry-leading” artificial intelligence (AI) capabilities and autonomous functions.

“Endovascular intervention is the gold-standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals. For these time-critical conditions, that’s devastating. Even when specialist intervention is available, treatment is often delayed, and complications are frustratingly common,” said David Bell, Remedy’s chief executive officer (CEO) and co-founder. “This funding will allow us to accelerate toward deployment of our N1 system so we can bring quality intervention to patients everywhere, regardless of geography.”

Data Collective Venture Capital (DCVC) led the present Series B funding, with participation from new investors including UC Investments, Skip Capital, and Hostplus, while existing investors Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures “doubled down”.

“Remedy Robotics represents a new generation of medical robotics and physical AI companies, focused not only on technical innovation, but on solving real-world challenges,” commented James Hardiman, general partner at DCVC. “We believe the company is uniquely positioned to redefine how lifesaving intervention is delivered, and are thrilled to support them as they advance toward broader clinical and commercial adoption.”

Remedy says it is finalising development of the N1 system—an AI-enabled robotic platform and software suite that uses machine learning to analyse preoperative imaging, simulate cases in advance, provide real-time 3D-2D image registration, and complete entire endovascular procedures robotically. Designed for onsite, remote or autonomous operation, the system has the potential to dramatically expand access to and improve the quality of specialised neurovascular, coronary and peripheral vascular care, the company further claims.

“This funding will allow our world-leading hardware, software and machine learning teams to progress the N1 system towards clinical trials and potential FDA approval, while also developing additional features including full autonomy,” said Jake Sganga, chief technology officer (CTO) and co-founder of Remedy. “We are particularly excited to deepen our partnership with the University of California, having worked closely with their clinical experts since 2021, and as we prepare for our planned pivotal clinical trials to be held across the UC network.”

“Remedy is building the kind of company we look for at Blackbird: one with world-class technical talent, a massive global problem to solve, and the potential to create an entirely new category,” added Michael Tolo, partner at Blackbird. “We believe Remedy is uniquely positioned to transform how endovascular care is delivered, and we are excited to support the company through its next phase of growth.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here